241
Views
13
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Comparison Between PPOS and GnRHa-Long Protocol in Clinical Outcome with the First IVF/ICSI Cycle: A Randomized Clinical Trial

, ORCID Icon, , &
Pages 261-272 | Published online: 03 Mar 2020

References

  • Dada T, Salha O, Baillie HS, Sharma V. A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study. Hum Reprod. 1999;14(2):288–293. doi:10.1093/humrep/14.2.28810099965
  • Caspi E, Ron-El R, Golan A, et al. Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins. Fertil Steril. 1989;51(1):95–99. doi:10.1016/S0015-0282(16)60435-12521328
  • Ren J, Sha A, Han D, Li P, Geng J, Ma C. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment? Fertil Steril. 2014;102(1):75–81. doi:10.1016/j.fertnstert.2014.03.03024746740
  • Albuquerque LE, Saconato H, Maciel MC. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev. 2005;1:Cd002808.
  • Oyesanya OA, Teo SK, Quah E, Abdurazak N, Lee FY, Cheng WC. Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: a comparison between a single dose of Zoladex depot and multiple daily doses of suprefact. Hum Reprod. 1995;10(5):1042–1044. doi:10.1093/oxfordjournals.humrep.a1360907657737
  • Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62–70 e3. doi:10.1016/j.fertnstert.2015.03.02225956370
  • Lu X, Hong Q, Sun L, et al. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Fertil Steril. 2016;106(6):1356–1362. doi:10.1016/j.fertnstert.2016.07.106827490046
  • Qin N, Chen Q, Hong Q, et al. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril. 2016;106(2):334–341.e1. doi:10.1016/j.fertnstert.2016.04.00627114329
  • Henkel RR, Schill WB. Sperm preparation for ART. Reprod Biol Endocrinol. 2003;1:108. doi:10.1186/1477-7827-1-10814617368
  • Cummins JM, Breen TM, Harrison KL, Shaw JM, Wilson LM, Hennessey JF. A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J In Vitro Fert Embryo Transf. 1986;3(5):284–295. doi:10.1007/BF01133388
  • Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33(2):229–237.29300975
  • Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine (Baltimore). 2016;95(9):e2939. doi:10.1097/MD.000000000000293926945402
  • Zhu X, Ye H, Fu Y. The utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine (Baltimore). 2016;95(28):e4193. doi:10.1097/MD.000000000000419327428219
  • Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90(5 Suppl):S188–S193. doi:10.1016/j.fertnstert.2008.08.03419007627
  • Orvieto R. Triggering final follicular maturation–hCG, GnRH-agonist or both, when and to whom? J Ovarian Res. 2015;8:60. doi:10.1186/s13048-015-0187-626293447
  • Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73(5):901–907. doi:10.1016/S0015-0282(00)00492-110785214
  • Abdalla HI, Ah-Moye M, Brinsden P, Howe DL, Okonofua F, Craft I. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertil Steril. 1987;48(6):958–963. doi:10.1016/S0015-0282(16)59591-03119376
  • Zhang J, Mao X, Wang Y, et al. Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Arch Gynecol Obstet. 2017;296(6):1207–1217. doi:10.1007/s00404-017-4537-z28948397